What the Media Gets Wrong When Reporting on “Overprescribing”

Say the word overprescribing in a headline and everyone instantly knows who the villain is supposed to be. The story almost writes itself: too many pills, too many careless doctors, too many bad outcomes. Clean, dramatic, clickable. The problem is that real health policy is rarely that tidy, and pain care is messier than a crime show montage with ominous background music.

Yes, reckless prescribing happened. Yes, aggressive promotion of opioid painkillers helped fuel the first wave of the opioid crisis. And yes, journalism should absolutely keep exposing bad actors, dangerous incentives, and sloppy medicine. But when coverage treats every opioid prescription as evidence of moral failure, or every pain doctor as a suspect with a prescription pad, it stops informing the public and starts flattening reality.

That flattening matters. It shapes policy. It shapes fear. It shapes how clinicians practice, how pharmacists fill, how insurers deny, and how patients with legitimate pain get treated when they walk into a clinic already feeling like they need to apologize for existing. So let’s talk about what the media often gets wrong when reporting on overprescribing, and why better reporting would help both public health and actual human beings.

The Biggest Mistake: Treating “Overprescribing” Like One Simple Thing

Media coverage often uses overprescribing as if it were a diagnosis with no lab work needed. But the term can mean several very different things.

• A clearly inappropriate prescription with no solid clinical reason.
• A prescription that is medically reasonable but longer or stronger than needed.
• A high dose given to a stable long-term patient whose case is complicated, not careless.
• A policy disagreement about what counts as “too much” in different settings.
• A retrospective judgment made after a bad outcome, even when the original decision was not obviously negligent.

Those are not the same story. But in many articles, they get thrown into one crowded trench coat and sent out to represent “the prescribing problem.” The result is confusion. Readers are left with the impression that any opioid use is proof of bad medicine, when in reality pain treatment lives in a world of tradeoffs, patient history, diagnosis, function, risk factors, monitoring, and alternatives that may or may not actually be available.

The Timeline Gets Blurred

What the media gets right

The early phase of the opioid crisis really was tied to prescribing. That part is not a myth, and pretending otherwise would be dishonest. Increased opioid prescribing in the 1990s and 2000s helped create risk, exposure, dependence, and diversion. If a report says the first wave of the crisis involved prescription opioids, that is fair.

What the media often gets wrong

Where coverage goes sideways is when it acts like the crisis never changed. The public-health picture today is not identical to the one from 2003 or 2010. Current overdose patterns are driven far more by illicitly manufactured fentanyl and an increasingly contaminated drug supply than by a doctor writing a straightforward prescription for a post-op patient or a carefully monitored chronic pain patient.

That distinction is not hair-splitting. It is the difference between treating a time-lapsed epidemic like a frozen screenshot. When the media talks as if “too many prescriptions” still explains most overdose deaths today, it gives the audience an outdated map for a moving storm.

Better reporting would say this plainly: prescribing was central to the first wave, but the present crisis is broader, deadlier, and much more shaped by illicit fentanyl, counterfeit pills, and polysubstance use. That is not a defense of irresponsible prescribing. It is a defense of chronology, which journalism is generally supposed to enjoy.

Coverage Often Confuses Dependence, Tolerance, Misuse, and Addiction

This is one of the most common and most damaging reporting errors. A patient can become physically dependent on an opioid without having opioid use disorder. A patient can develop tolerance without being addicted. A patient can misuse medication without matching the full clinical picture of addiction. Those distinctions are not technical trivia; they affect treatment, stigma, and policy.

Unfortunately, some stories still slide from “takes opioids long term” to “addicted” with the elegance of a banana peel on a staircase. That language may create drama, but it does not create understanding. It also makes patients afraid to be honest with clinicians about pain control, withdrawal symptoms, or medication concerns.

Good reporting should define terms, not weaponize them. If a story is about opioid use disorder, say that. If it is about dependence, say that. If it is about unsafe prescribing patterns, spell out what made them unsafe. Precision is not boring. Precision is what keeps public conversation from becoming a fog machine.

The CDC Guideline Is Not a Set of Handcuffs

Another major media miss is treating opioid guidance as a rigid lawbook. The 2022 CDC clinical guideline was written as voluntary, patient-centered guidance. It specifically warns against being used as an inflexible standard of care, a hard legal ceiling, or a reason for abrupt discontinuation. It also makes clear that it excludes several important contexts, including cancer-related pain, sickle cell disease, palliative care, and end-of-life care.

Yet coverage sometimes presents dosage thresholds like magical red lines. Cross this number and you are reckless. Fall below it and everyone gets a gold star. That is not how the guideline frames it. The guideline treats dosage recommendations as clinical guideposts, not absolute rules. It emphasizes individualized assessment, shared decision-making, and careful weighing of benefits and risks.

In plain English, the message is not “numbers do not matter.” They do. The message is “numbers do not replace judgment.” A headline that ignores that nuance may help fill airtime, but it does not help a family physician making a complicated decision for a patient with multiple conditions, years of treatment history, and limited access to alternatives.

Stories About Cutting Prescriptions Often Ignore the Harm of Cutting Too Fast

There is a recurring media template that goes like this: prescriptions go down, therefore safety goes up. That sounds reasonable until you remember that human beings are not dimmer switches you can yank to “off” without consequences.

Federal health agencies have repeatedly warned that rapid tapering or sudden discontinuation can cause withdrawal, worsened pain, psychological distress, and other harms. Patients who are physically dependent may end up destabilized, desperate, or pushed toward unsafe sources. Some coverage mentions tapering as though it is automatically a clean fix, when the real-world evidence says badly managed tapering can itself become a medical problem.

This does not mean tapering is bad. Sometimes it is absolutely appropriate. Sometimes it is overdue. Sometimes it is lifesaving. But tapering is a clinical process, not a punishment ritual. When journalism frames dose reduction as inherently virtuous and any hesitation as suspicious, it misses the very patient-centered caution federal guidance keeps trying to underline with the desperation of someone highlighting the same sentence three times.

Chronic Pain Barely Gets a Starring Role

One reason overprescribing stories often feel skewed is that chronic pain itself gets treated like background wallpaper. But chronic pain is not niche. It affects tens of millions of Americans and hits some groups harder than others, including older adults, women, people living in poverty, and people in rural areas.

When the media skips past that burden, pain patients become abstract props in a policy argument instead of central subjects. Coverage becomes all supply, no suffering. All diversion, no disability. All risk, no function. It is easier to talk about “pill volume” than to describe what it means to live with severe spinal disease, neuropathy, sickle cell pain episodes, debilitating osteoarthritis, or the kind of daily pain that quietly eats sleep, work, movement, mood, and identity.

That omission matters because it changes the emotional logic of the story. Once pain disappears from the frame, any prescription looks suspicious by default. Once pain is visible again, the public can see the real policy challenge: reducing harm without abandoning people who still need treatment.

Nonopioid Alternatives Are Often Mentioned Like They Grow on Trees

Journalists love a sentence like, “Patients should try nonopioid alternatives first.” And in principle, that is often sensible. Exercise therapy, psychological approaches, multidisciplinary rehabilitation, certain nonopioid medications, and other noninvasive options can help many patients depending on the condition.

But here is the part coverage often skips: alternatives are not always accessible, affordable, fast, or covered. Telling a patient to use physical therapy is a lovely plan until the insurance plan approves six visits and the nearest clinic has a six-week wait. Recommending multidisciplinary pain care sounds great until the patient lives in a rural county where “multidisciplinary” means one overworked primary care clinician and a search engine.

Some alternatives work well for some conditions. Some provide modest benefit. Some require time, transportation, childcare, money, and provider availability that many people simply do not have. So when reporting implies the choice is between risky opioids and a well-stocked buffet of easy, effective alternatives, it paints a fantasy version of the health system. Nice fantasy. Wrong health system.

Coverage Loves Scandal More Than Systems

It is easier to build a gripping article around a rogue prescriber than around insurance design, fragmented pain care, workforce shortages, or pharmacy policy. That is understandable. Systems make worse villains. They do not wear sunglasses indoors or own suspiciously large boats.

But the obsession with scandal can distort the public’s understanding of what actually drives harm. Overdose risk, pain undertreatment, access barriers, abrupt tapering, and treatment gaps do not come only from one reckless doctor. They also come from payer limits, pharmacy refusals, patchwork state rules, stigma, poor addiction treatment access, and the failure to build a serious pain-care infrastructure in the first place.

In other words, “overprescribing” is sometimes a prescribing story, but often it is also a systems story. When news reports ignore those systems, the audience gets a blame narrative instead of a useful one.

What Better Reporting Would Actually Look Like

Here is a simple test. Any article about overprescribing should answer at least most of these questions:

• Which patients? Acute pain, chronic pain, cancer care, palliative care, post-surgical care, or opioid use disorder treatment?
• Which time period? The early prescription-driven phase of the crisis or the current illicit fentanyl era?
• Which harm? Diversion, overdose, undertreated pain, withdrawal, patient abandonment, or all of the above?
• Compared to what? What nonopioid options were realistically available and covered?
• What outcome matters? Pain scores, function, overdose risk, quality of life, employment, sleep, or hospitalizations?

That kind of reporting would not be softer. It would be better. It would help readers understand that a policy can reduce one kind of risk while creating another. It would show that “fewer prescriptions” is not the same thing as “better care.” And it would stop pretending that a complicated clinical landscape can be summarized with a single scary noun.

Conclusion

The media is not wrong to scrutinize opioid prescribing. It would be irresponsible not to. But scrutiny without context turns into distortion, and distortion makes bad policy easier to sell. The overprescribing story is not false; it is often incomplete.

The fuller story is harder and more honest. Prescription opioids played a major role in the first wave of the crisis. Current overdose deaths are driven far more by illicit fentanyl and a toxic drug supply. Chronic pain remains widespread and unevenly treated. Guidance is voluntary and patient-centered, not a one-size-fits-all law. Tapering can help, but done badly it can also harm. Alternatives matter, but access matters too.

That is the version the public needs. Not because nuance is fashionable, but because people are making laws, clinical decisions, and personal judgments based on these stories. And if reporting is going to carry that much weight, it should at least stop acting like every pain-care question can be answered by shouting “overprescribing” and sprinting toward the next headline.

Real-World Experiences the Headlines Often Miss

Here is what this debate looks like away from press conferences and policy panels. A middle-aged woman with severe back pain has taken the same stable medication dose for years. She works part time, cares for a parent, and says the medicine does not make her euphoric; it makes grocery shopping possible. Then a new clinic policy arrives. Suddenly, she is treated less like a patient and more like a legal risk in sneakers. No one asks what improved her function. No one asks what alternatives failed. The conversation becomes about the number on the chart, not the life around it.

Then there is the primary care doctor in a packed community clinic. The doctor has fifteen minutes, a waiting room full of patients, an insurer that resists covering multidisciplinary pain care, and a genuine fear of doing harm. This clinician is not trying to be careless. This clinician is trying to balance pain relief, overdose risk, documentation requirements, pharmacy scrutiny, and state expectations while also remembering whether lunch happened. When media stories reduce everything to “bad prescribing,” they erase the impossible design of the system many clinicians are working inside.

Pharmacists live in a similar squeeze. Some are expected to act as gatekeepers, compliance officers, counselors, and mind readers all at once. A legitimate prescription may trigger suspicion because the dose looks high, the patient traveled from another county, or the timing is a little unusual. Sometimes that caution prevents harm. Sometimes it leaves a patient in tears at the counter after surgery or during a pain flare. Those moments rarely become national headlines, but they shape how the crisis is felt in ordinary life.

Families also experience the confusion created by sloppy reporting. One family may hear constant warnings about doctor prescribing and assume prescription bottles are still the central danger in every case, while another family loses a teenager or young adult to a counterfeit pill bought outside the medical system entirely. Both tragedies belong in public conversation, but they are not the same mechanism, and they do not demand the same response. When the media blurs them together, families are left with fear but not clarity.

Patients with chronic pain often describe the same emotional whiplash: they know opioids carry risk, they do not want to be harmed, and many actively want more treatment options. What they do not want is to be told that the existence of past overprescribing means their current pain no longer deserves thoughtful care. That is the hidden injury in a lot of overprescribing coverage. It can leave people feeling as though the public has decided they are either naive, dangerous, or inconvenient.

And that is why better reporting matters. Not because it should be softer on medicine, but because it should be truer to experience. The public deserves reporting that can hold two ideas at once: some prescribing was absolutely too loose, and some reactions became too blunt. Patients deserve stories that recognize both addiction risk and untreated pain. Clinicians deserve coverage that separates negligence from complexity. And readers deserve journalism that explains the crisis as it is, not as it fits best into a tidy headline.

SEO Tags